Rubio Teresa
Office of Health & Constituent Affairs, U.S. Food and Drug Administration.
Hosp Pharm. 2016 Mar;51(3):268. doi: 10.1310/hpj5103-268. Epub 2016 Mar 1.
As part of the US Food and Drug Administration's MedWatch program, safety labeling changes are reviewed and compiled monthly for drugs and therapeutic biologics where important changes have been made to the safety information. Boxed warnings (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075096.pdf) are ordinarily used to highlight either adverse reactions so serious in proportion to the potential benefit from the drug that it is essential that it be considered in assessing the risks and benefits of using the drugs or serious adverse reactions that can be prevented/reduced in frequency or severity by appropriate use of the drug; or FDA approved the drug with restrictions to ensure safe use because FDA concluded that the drug can be safely used only if distribution or use is restricted. There was 1 revised boxed warning from October to December 2015.
作为美国食品药品监督管理局(FDA)药品安全监测计划(MedWatch)的一部分,每月会对药品和治疗性生物制品的安全标签变更进行审查和汇总,这些药品和生物制品的安全信息已发生重大变化。黑框警告(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075096.pdf)通常用于突出显示以下两类不良反应:一类是与药物潜在益处相比严重程度极高,以至于在评估用药的风险和益处时必须加以考虑的不良反应;另一类是通过适当用药可预防/降低发生频率或严重程度的严重不良反应;或者FDA批准该药物时附带限制条件以确保安全使用,因为FDA认定只有在限制药物分发或使用的情况下才能安全用药。2015年10月至12月有1条修订后的黑框警告。